Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $8.77 USD
Change Today -0.29 / -3.20%
Volume 187.3K
STAA On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

staar surgical co (STAA) Snapshot

Open
$9.03
Previous Close
$9.06
Day High
$9.10
Day Low
$8.65
52 Week High
08/1/14 - $12.73
52 Week Low
01/27/15 - $4.84
Market Cap
340.7M
Average Volume 10 Days
116.1K
EPS TTM
$-0.19
Shares Outstanding
38.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for STAAR SURGICAL CO (STAA)

Related News

No related news articles were found.

staar surgical co (STAA) Related Businessweek News

No Related Businessweek News Found

staar surgical co (STAA) Details

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells implantable lenses for the eye, and delivery systems to deliver lenses into the eye. The company offers implantable collamer lenses (ICL) comprising Visian ICL to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also provides invasive intraocular lenses (IOL) that include aspheric IOLs that produce a clearer image than traditional spherical lenses; nanoFLEX IOL, a single piece collamer aspheric optic; Toric IOL for cataract patients to treat pre-existing astigmatism; and Preloaded Injector, a silicone or acrylic IOL preloaded into a single-use disposable injector. In addition, the company sells surgical products, and other related instruments and devices; and manufactures AquaFlow device for the treatment of glaucoma. It markets its products to health care providers, including surgical centers, hospitals, managed care providers, health maintenance organizations, group purchasing organizations, and government facilities. The company offers its products primarily under the STAAR, Visian, Collamer, CentraFLOW, AquaPORT, nanoFLEX, nanoPOINT, Epiphany, and AquaFlow names. It sells products directly through its sales representatives in the United States, Canada, Japan, and Spain, as well as through independent distributors in approximately 60 countries worldwide. STAAR Surgical Company was founded in 1982 and is headquartered in Monrovia, California.

300 Employees
Last Reported Date: 07/29/15
Founded in 1982

staar surgical co (STAA) Top Compensated Officers

Chief Financial Officer and Vice President
Total Annual Compensation: $303.8K
Chief Accounting Officer and Vice President
Total Annual Compensation: $334.4K
Vice President of Business Development, Corpo...
Total Annual Compensation: $336.2K
Vice President of Global Marketing
Total Annual Compensation: $266.2K
Compensation as of Fiscal Year 2014.

staar surgical co (STAA) Key Developments

STAAR Surgical Company Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended July 3, 2015

STAAR Surgical Company reported unaudited consolidated earnings results for the second quarter and six months ended July 3, 2015. For the quarter, net sales were $18,657,000 against $20,048,000 a year ago. Operating loss was $1,743,000 against $1,390,000 a year ago. Loss before provision for income taxes was $1,446,000 against $1,422,000 a year ago. Net loss was $1,599,000 against $1,789,000 a year ago. Net loss per share - basic and diluted was $0.04 against $0.05 a year ago. Net income - (adjusted) was $167,000 against $291,000 a year ago. Net income per share, basic - (adjusted) was $0.00 against $0.01 a year ago. Net income per share, diluted - (adjusted) was $0.00 against $0.01 a year ago. For the six months, net sales were $37,514,000 against $40,226,000 a year ago. Operating loss was $3,252,000 against $2,732,000 a year ago. Loss before provision for income taxes was $3,812,000 against $2,562,000 a year ago. Net loss was $3,938,000 against $3,148,000 a year ago. Net loss per share - basic and diluted was $0.10 against $0.08 a year ago. Net cash used in operating activities was $1,405,000 against $4,064,000 a year ago. Acquisition of property and equipment was $701,000 against $2,269,000 a year ago. Net income - (adjusted) was $1,154,000 against $1,929,000 a year ago. Net income per share, basic - (adjusted) was $0.03 against $0.05 a year ago. Net income per share, diluted - (adjusted) was $0.03 against $0.05 a year ago.

STAAR Surgical Company Appoints Jon K. Hayashida as Vice President of Global Clinical and Medical Affairs

STAAR Surgical Company announced that it has named Dr. Jon K. Hayashida to the newly created position of Vice President of Global Clinical and Medical Affairs. In this position he will head the company's strategic initiative in building exceptional clinical validation and clinical utility for the company's continuum of lenses for the myopic, presbyopic and cataract vision care markets. Dr. Hayashida's professional career includes experience in corporate eye care, ophthalmic start-up companies and direct patient care. He held the position of Vice President of Clinical and Medical Affairs for Bausch and Lomb, Surgical, where he gained FDA approvals for both the Glistening-free Envista Hydrophobic Acrylic IOL and PMA approval for the Trulign Toric Accommodating IOL. He also held Clinical Affairs leadership and research positions with Cooper Vision and Allergan. His Ophthalmic start-up company experience includes Vice President Clinical Affairs for Wavetec Vision, Transcent Medical and Refractec where he directed, planned and executed successful FDA PMA approvals. Dr. Hayashida has served as a clinical care specialist at the UCLA Laser Refractive Center, Jules Stein Institute, UCLA School of Medicine. He has served most recently as Vice President of Programs and Services for the Braille Institute of America.

STAAR Surgical Company to Report Q2, 2015 Results on Jul 29, 2015

STAAR Surgical Company announced that they will report Q2, 2015 results on Jul 29, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STAA:US $8.77 USD -0.29

STAA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bovie Medical Corp $2.31 USD +0.17
Ellex Medical Lasers Ltd A$0.32 AUD -0.015
Glaukos Corp $31.79 USD -0.53
IRIDEX Corp $7.16 USD +0.13
Vascular Solutions Inc $37.23 USD +0.03
View Industry Companies
 

Industry Analysis

STAA

Industry Average

Valuation STAA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.9x
Price/Book 8.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STAAR SURGICAL CO, please visit www.staar.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.